Ibrutinib in the Treatment of Solid Tumors: Current State of Knowledge and Future Directions

Bruton's Tyrosine Kinase (Btk) is considered crucial in the activation and survival of both physiological and malignant B-cells. In recent years, ibrutinib, an oral Btk Inhibitor, became a breakthrough therapy for hematological malignancies, such as chronic lymphocytic. However, ibrutinib's feasibility might not end there. Several other kinases with established involvement with solid malignancies (i.e., EGFR, HER2) have been found to be inhibited by this agent. Recent discoveries indicate that Btk is a potential anti-solid tumor therapy target. Consequently, ibrutinib, a BTK-inhibitor, has been studied as a therapeutic option in solid malignancies. While most preclinical studies indicate ibrutinib to be an effective therapeutic option in some specific indications, such as NSCLC and breast Cancer, clinical trials contradict these observations. Nevertheless, while ibrutinib failed as a monotherapy, it might become an interesting part of a multidrug regime: not only has a synergism between ibrutinib and other compounds, such as trametinib or dactolisib, been observed in vitro, but this Btk Inhibitor has also been established as a radio- and chemosensitizer. This review aims to describe the milestones in translating Btk inhibitors to solid tumors in order to understand the future potential of this agent better.